CSF biomarkers for Alzheimer's disease: current utility and potential future use

Arai, 2000, CSF phosphorylated tau protein and mild cognitive impairment: a prospective study, Exp. Neurol, 166, 201, 10.1006/exnr.2000.7501 Arai, 1997, Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology, Biochem. Biophys. Res. Commun, 236, 262, 10.1006/bbrc.1997.6908 Blennow, 2004, CSF biomarkers for mild cognitive impairment, J. Intern. Med, 256, 224, 10.1111/j.1365-2796.2004.01368.x Blennow, 2001, CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease, Mol. Neurobiol, 24, 87, 10.1385/MN:24:1-3:087 Buée, 2000, Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res. Brain Res. Rev, 33, 95, 10.1016/S0165-0173(00)00019-9 Buerger, 2002, Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine, Arch. Neurol, 231, 59, 1267, 10.1001/archneur.59.8.1267 Cairns, 2009, Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report, Arch. Neurol, 66, 1557, 10.1001/archneurol.2009.279 2000 Craig-Schapiro, 2010, YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease, Biol Psychiatry, 68, 903, 10.1016/j.biopsych.2010.08.025 Crystal, 1988, Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease, Neurology, 38, 1682, 10.1212/WNL.38.11.1682 de Leon, 2007, Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease, Ann. N. Y. Acad. Sci, 1097, 114, 10.1196/annals.1379.012 Fagan, 2006, Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans, Ann. Neurol, 59, 512, 10.1002/ana.20730 Fagan, 2009, Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease, EMBO Mol. Med, 1, 371, 10.1002/emmm.200900048 Fagan, 2007, Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults, Arch. Neurol, 64, 343, 10.1001/archneur.64.3.noc60123 Gustafson, 2007, Cerebrospinal fluid beta-amyloid 1–42 concentration may predict cognitive decline in older women, J. Neurol. Neurosurg. Psychiatry, 78, 461, 10.1136/jnnp.2006.100529 Hampel, 2004, Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study, Arch. Gen. Psychiatry, 61, 95, 10.1001/archpsyc.61.1.95 Hansson, 2006, Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, Lancet Neurol, 5, 228, 10.1016/S1474-4422(06)70355-6 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Hesse, 2001, Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neurosci. Lett, 297, 187, 10.1016/S0304-3940(00)01697-9 Hu, 2002, Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay, Am. J. Pathol, 160, 1269, 10.1016/S0002-9440(10)62554-0 Jagust, 2009, Relationships between biomarkers in aging and dementia, Neurology, 73, 1193, 10.1212/WNL.0b013e3181bc010c Li, 2007, CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study, Neurology, 69, 631, 10.1212/01.wnl.0000267428.62582.aa Mattsson, 2009, CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment, JAMA, 302, 385, 10.1001/jama.2009.1064 Morris, 1993, The Clinical Dementia Rating (CDR): current version and scoring rules, Neurology, 43, 2412, 10.1212/WNL.43.11.2412-a Motter, 1995, Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease, Ann. Neurol, 38, 643, 10.1002/ana.410380413 Petersen, 1999, Mild cognitive impairment: clinical characterization and outcome, Arch. Neurol, 56, 303, 10.1001/archneur.56.3.303 Portelius, 2008, Characterization of tau in cerebrospinal fluid using mass spectrometry, J. Proteome Res, 7, 2114, 10.1021/pr7008669 Riemenschneider, 2002, Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment, Arch. Neurol, 59, 1729, 10.1001/archneur.59.11.1729 Rowe, 2007, Imaging beta-amyloid burden in aging and dementia, Neurology, 68, 1718, 10.1212/01.wnl.0000261919.22630.ea Shaw, 2009, Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects, Ann. Neurol, 65, 403, 10.1002/ana.21610 Shoji, 1998, Combination assay of CSF tau, A beta 1–40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease, J. Neurol. Sci, 158, 134, 10.1016/S0022-510X(98)00122-1 Skoog, 2003, Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds, Dement. Geriatr. Cogn. Disord, 15, 169, 10.1159/000068478 Snider, 2009, Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type, Arch. Neurol, 66, 638, 10.1001/archneurol.2009.55 Stomrud, 2007, Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly, Dement. Geriatr. Cogn. Disord, 24, 118, 10.1159/000105017 Sunderland, 2003, Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease, JAMA, 289, 2094, 10.1001/jama.289.16.2094 Sunderland, 1999, Longitudinal stability of CSF tau levels in Alzheimer patients, Biol. Psychiatry, 46, 750, 10.1016/S0006-3223(99)00143-2 Tapiola, 2009, Cerebrospinal fluid {beta}amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch. Neurol, 66, 382, 10.1001/archneurol.2008.596 Verbeek, 2009, Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy, Ann. Neurol, 66, 245, 10.1002/ana.21694 Welge, 2009, Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease, J. Neural Transm, 116, 203, 10.1007/s00702-008-0177-6